|
1
|
Padera TP, Kadambi A, di Tomaso E,
Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark
EJ, et al: Lymphatic metastasis in the absence of functional
intratumor lymphatics. Science. 296:1883–1886. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mitrovska S and Jovanova S: Low-molecular
weight heparin enoxaparin in the treatment of acute coronary
syndromes without ST segment elevation. Bratisl Lek Listy.
110:45–48. 2009.PubMed/NCBI
|
|
3
|
Mousa SA and Petersen LJ: Anti-cancer
properties of low-molecular-weight heparin: Preclinical evidence.
Thromb Haemost. 102:258–267. 2009.PubMed/NCBI
|
|
4
|
Icli F, Akbulut H, Utkan G, Yalcin B,
Dincol D, Isikdogan A, Demirkazik A, Onur H, Cay F and Büyükcelik
A: Low molecular weight heparin (LMWH) increases the efficacy of
cisplatinum plus gemcitabine combination in advanced pancreatic
cancer. J Surg Oncol. 95:507–512. 2007. View Article : Google Scholar
|
|
5
|
Yu CJ, Ye SJ, Feng ZH, Ou WJ, Zhou XK, Li
LD, Mao YQ, Zhu W and Wei YQ: Effect of Fraxiparine, a type of low
molecular weight heparin, on the invasion and metastasis of lung
adenocarcinoma A549 cells. Oncol Lett. 1:755–760. 2010.PubMed/NCBI
|
|
6
|
Carmazzi Y, Iorio M, Armani C, Cianchetti
S, Raggi F, Neri T, Cordazzo C, Petrini S, Vanacore R, Bogazzi F,
et al: The mechanisms of nadroparin-mediated inhibition of
proliferation of two human lung cancer cell lines. Cell Prolif.
45:545–556. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Niu Q, Wang W, Li Y, Ruden DM, Wang F, Li
Y, Wang F, Song J and Zheng K: Low molecular weight heparin ablates
lung cancer cisplatin-resistance by inducing proteasome-mediated
ABCG2 protein degradation. PLoS One. 7:e410352012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Seidensticker M, Seidensticker R, Damm R,
Mohnike K, Pech M, Sangro B, Hass P, Wust P, Kropf S, Gademann G,
et al: Prospective randomized trial of enoxaparin, pentoxifylline
and ursodeoxycholic acid for prevention of radiation-induced liver
toxicity. PLoS One. 9:e1127312014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bae SM, Kim JH, Chung SW, Byun Y, Kim SY,
Lee BH, Kim IS and Park RW: An apoptosis-homing peptide-conjugated
low molecular weight heparin-taurocholate conjugate with antitumor
properties. Biomaterials. 34:2077–2086. 2013. View Article : Google Scholar
|
|
10
|
Erduran E, Tekelioğlu Y, Gedik Y and
Yildiran A: Apoptotic effects of heparin on lymphoblasts,
neutrophils, and mononuclear cells: Results of a preliminary in
vitro study. Am J Hematol. 61:90–93. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jadhav U and Mohanam S: Response of
neuroblastoma cells to ionizing radiation: Modulation of in vitro
invasiveness and angiogenesis of human microvascular endothelial
cells. Int J Oncol. 29:1525–1531. 2006.PubMed/NCBI
|
|
12
|
Kaliski A, Maggiorella L, Cengel KA, Mathe
D, Rouffiac V, Opolon P, Lassau N, Bourhis J and Deutsch E:
Angiogenesis and tumor growth inhibition by a matrix
metalloproteinase inhibitor targeting radiation-induced invasion.
Mol Cancer Ther. 4:1717–1728. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park CM, Park MJ, Kwak HJ, Lee HC, Kim MS,
Lee SH, Park IC, Rhee CH and Hong SI: Ionizing radiation enhances
matrix metalloproteinase-2 secretion and invasion of glioma cells
through Src/epidermal growth factor receptor-mediated p38/Akt and
phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res.
66:8511–8519. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhai GG, Malhotra R, Delaney M, Latham D,
Nestler U, Zhang M, Mukherjee N, Song Q, Robe P and Chakravarti A:
Radiation enhances the invasive potential of primary glioblastoma
cells via activation of the Rho signaling pathway. J Neurooncol.
76:227–237. 2006. View Article : Google Scholar
|
|
15
|
Camphausen K, Moses MA, Beecken WD, Khan
MK, Folkman J and O'Reilly MS: Radiation therapy to a primary tumor
accelerates metastatic growth in mice. Cancer Res. 61:2207–2211.
2001.PubMed/NCBI
|
|
16
|
Norrby K: Low-molecular-weight heparins
and angiogenesis. APMIS. 114:79–102. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Debergh I, Van Damme N, Pattyn P, Peeters
M and Ceelen WP: The low-molecular-weight heparin, nadroparin,
inhibits tumour angiogenesis in a rodent dorsal skinfold chamber
model. Br J Cancer. 102:837–843. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kakkar AK, Levine MN, Kadziola Z, Lemoine
NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M and Williamson
RC: Low molecular weight heparin, therapy with dalteparin, and
survival in advanced cancer: The fragmin advanced malignancy
outcome study (FAMOUS). J Clin Oncol. 22:1944–1948. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Altinbas M, Coskun HS, Er O, Ozkan M, Eser
B, Unal A, Cetin M and Soyuer S: A randomized clinical trial of
combination chemotherapy with and without low-molecular-weight
heparin in small cell lung cancer. J Thromb Haemost. 2:1266–1271.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Klerk CP, Smorenburg SM, Otten HM, Lensing
AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van
Tienhoven G, et al: The effect of low molecular weight heparin on
survival in patients with advanced malignancy. J Clin Oncol.
23:2130–2135. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tuxhorn JA, McAlhany SJ, Yang F, Dang TD
and Rowley DR: Inhibition of transforming growth factor-beta
activity decreases angiogenesis in a human prostate cancer-reactive
stroma xenograft model. Cancer Res. 62:6021–6025. 2002.PubMed/NCBI
|
|
22
|
Li C, Guo B, Bernabeu C and Kumar S:
Angiogenesis in breast cancer: The role of transforming growth
factor beta and CD105. Microsc Res Tech. 52:437–449. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kanekura T and Chen X: CD147/basigin
promotes progression of malignant melanoma and other cancers. J
Dermatol Sci. 57:149–154. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Weidle UH, Scheuer W, Eggle D, Klostermann
S and Stockinger H: Cancer-related issues of CD147. Cancer Genomics
Proteomics. 7:157–169. 2010.PubMed/NCBI
|
|
25
|
Wu J, Li Y, Dang YZ, Gao HX, Jiang JL and
Chen ZN: HAb18G/CD147 promotes radioresistance in hepatocellular
carcinoma cells: A potential role for integrin β1 signaling. Mol
Cancer Ther. 14:553–563. 2015. View Article : Google Scholar
|
|
26
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tamm I, Wang Y, Sausville E, Scudiero DA,
Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin
inhibits caspase activity and apoptosis induced by Fas (CD95), Bax,
caspases, and anticancer drugs. Cancer Res. 58:5315–5320.
1998.PubMed/NCBI
|
|
28
|
Suzuki A, Ito T, Kawano H, Hayashida M,
Hayasaki Y, Tsutomi Y, Akahane K, Nakano T, Miura M and Shiraki K:
Survivin initiates procaspase 3/p21 complex formation as a result
of interaction with Cdk4 to resist Fas-mediated cell death.
Oncogene. 19:1346–1353. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li F, Ambrosini G, Chu EY, Plescia J,
Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and
mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Skoufias DA, Mollinari C, Lacroix FB and
Margolis RL: Human survivin is a kinetochore-associated passenger
protein. J Cell Biol. 151:1575–1582. 2000. View Article : Google Scholar
|
|
31
|
Suzuki A, Hayashida M, Ito T, Kawano H,
Nakano T, Miura M, Akahane K and Shiraki K: Survivin initiates cell
cycle entry by the competitive interaction with Cdk4/p16(INK4a) and
Cdk2/cyclin E complex activation. Oncogene. 19:3225–3234. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nassar A, Lawson D, Cotsonis G and Cohen
C: Survivin and caspase-3 expression in breast cancer: Correlation
with prognostic parameters, proliferation, angiogenesis, and
outcome. Appl Immunohistochem Mol Morphol. 16:113–120. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Monzó M, Rosell R, Felip E, Astudillo J,
Sánchez JJ, Maestre J, Martín C, Font A, Barnadas A and Abad A: A
novel anti-apoptosis gene: Re-expression of survivin messenger RNA
as a prognosis marker in non-small-cell lung cancers. J Clin Oncol.
17:2100–2104. 1999.PubMed/NCBI
|
|
34
|
Kren L, Brazdil J, Hermanova M, Goncharuk
VN, Kallakury BV, Kaur P and Ross JS: Prognostic significance of
anti-apoptosis proteins survivin and bcl-2 in non-small cell lung
carcinomas: A clinicopathologic study of 102 cases. Appl
Immunohistochem Mol Morphol. 12:44–49. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yoshida H, Sumi T, Hyun Y, Nakagawa E,
Hattori K, Yasui T, Morimura M, Honda K, Nakatani T and Ishiko O:
Expression of survivin and matrix metalloproteinases in
adenocarcinoma and squamous cell carcinoma of the uterine cervix.
Oncol Rep. 10:45–49. 2003.
|
|
36
|
Ikeguchi M, Liu J and Kaibara N:
Expression of survivin mRNA and protein in gastric cancer cell line
(MKN-45) during cisplatin treatment. Apoptosis. 7:23–29. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jin XD, Gong L, Guo CL, Hao JF, Wei W, Dai
ZY and Li Q: Survivin expressions in human hepatoma HepG2 cells
exposed to ionizing radiation of different LET. Radiat Environ
Biophys. 47:399–404. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rödel F, Reichert S, Sprenger T, Gaipl US,
Mirsch J, Liersch T, Fulda S and Rödel C: The role of survivin for
radiation oncology: Moving beyond apoptosis inhibition. Curr Med
Chem. 18:191–199. 2011. View Article : Google Scholar
|
|
39
|
Rödel C, Haas J, Groth A, Grabenbauer GG,
Sauer R and Rödel F: Spontaneous and radiation-induced apoptosis in
colorectal carcinoma cells with different intrinsic
radiosensitivities: Survivin as a radioresistance factor. Int J
Radiat Oncol Biol Phys. 55:1341–1347. 2003. View Article : Google Scholar : PubMed/NCBI
|
